Drugs / CG-BM1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07632599 | Jul 2026 → Jun 2027 expected | ankylosing spondylitis | Eighth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07865676 | Apr 2026 → Jun 2029 expected | muscular atrophy | Guangzhou Cellgenes Biotechnology Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06740149 | Mar 2023 → Mar 2026 | liver disorder | Sun Yat-sen University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CG-BM1 | “CG-BM1 is a bone marrow mesenchymal stem cell product independently developed by Guangzhou Cellgenes Biotechnology Co., Ltd.” NCT06740149 ↗ |
| Modality | Cell therapy | “CG-BM1 is a bone marrow mesenchymal stem cell product” NCT06740149 ↗ |
| Route | Intravenous | “Administered intravenously.” NCT06740149 ↗ |